{
    "nct_id": "NCT02988440",
    "official_title": "A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)",
    "inclusion_criteria": "* Histologically or cytologically confirmed advanced (unresectable and/or metastatic) HCC\n* Patients with advanced HCC not amenable for surgical or loco-regional treatment\n* At least one measureable tumor lesion that that has not been previously locally\n* Patients with current cirrhotic status of Child-Pugh class A only (5-6 points with total bilirubin < 2 mg/dL for dose-escalation) with no encephalopathy and no clinical ascites (ascites controlled by diuretics is also excluded in this study).\n* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patient must meet required laboratory values at the screening\n* Normal electrocardiogram at screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n* Invasion of the main portal vein and/or tumor involvement in more than 50% of the liver (applicable only for the dose-escalation part)\n* Patients with Portal-caval shunts\n* Prior or concomitant systemic anti-cancer treatment for advanced disease\n* Systemic chronic steroid therapy (â‰¥ 10mg/day prednisone or equivalent) or any immunosuppressive therapy 7 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.\n* Cardiac or cardiac repolarization abnormality\n* Patients with active Hepatitis B infection (HBsAg positive) that are not receiving antiviral treatment are excluded\n* Patients with positive test for hepatitis C ribonucleic acid (HCV RNA)\n* Loco-regional treatment within 4 weeks prior to initiation of study treatment.",
    "miscellaneous_criteria": ""
}